Literature DB >> 6599715

The effects of BTS 49465 on blood pressure and peripheral arteriolar and venous tone in normal volunteers.

A J Cowley, R D Wynne, J R Hampton.   

Abstract

The pharmacokinetics and cardiovascular effects of a new vasodilator, BTS 49465 (7-fluoro-1-methyl-3-methylsulphinyl-4-quinolone) were evaluated in a double-blind placebo-controlled manner in a group of normal male volunteers. Forearm vascular resistance and forearm venous tone were measured by venous occlusion plethysmography using mercury-in-rubber strain gauges, supine, and in response to lower body negative pressure. Systemic arterial pressure was also measured. Dose-dependent reductions in blood pressure were observed both supine and in response to lower body negative pressure. Measurements of forearm vascular resistance and forearm venous tone suggested the drug caused both arteriolar and venous vasodilatation. Plasma level measurements indicated that the active metabolite of BTS 49465 had a prolonged half-life. BTS 49465 is a mixed arteriolar and venous vasodilator which may be suitable for once-daily administration. Measurement of limb vascular tone is a useful means of evaluating the effects of vasodilators.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6599715

Source DB:  PubMed          Journal:  J Hypertens Suppl        ISSN: 0952-1178


  8 in total

1.  Flosequinan for congestive heart failure: what promise does it hold?

Authors:  J R Hampton
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

2.  Duration and reproducibility of initial hemodynamic effects of flosequinan in patients with congestive heart failure.

Authors:  G L Bartels; W J Remme; A C Wiesfeld; F J Kok; M P Look; X H Krauss; H A Kruyssen
Journal:  Cardiovasc Drugs Ther       Date:  1990-06       Impact factor: 3.727

3.  The pharmacokinetics and haemodynamics of BTS 49 465 and its major metabolite in healthy volunteers.

Authors:  R D Wynne; E L Crampton; I D Hind
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

4.  Mechanisms of the contractile effects of flosequinoxan.

Authors:  N Zimmermann; G S Bodor; P Boknik; E Gams; L R Jones; J Neumann; H Scholz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1995-04       Impact factor: 3.000

Review 5.  Vasodilators. A re-evaluation of their role in heart failure.

Authors:  L W Stevenson; G Fonarow
Journal:  Drugs       Date:  1992-01       Impact factor: 9.546

6.  Flosequinan as a third agent for the treatment of hypertension: a placebo controlled, double-blind study.

Authors:  A J Cowley; R D Wynne; J R Hampton
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

7.  Effect of flosequinan on exercise capacity and cardiac function in patients with chronic mild heart failure: a double-blind placebo-controlled study.

Authors:  M Hori; H Sato; H Ozaki; M Inoue; M Naka; M Fukunami; M Fukushima; K Kunisada
Journal:  Heart Vessels       Date:  1992       Impact factor: 2.037

8.  Lack of pharmacodynamic interactions between acute dose flosequinan and xamoterol. A pilot study in healthy subjects.

Authors:  H W Ng; T J Walley; Y Tsao; A M Breckenridge
Journal:  Eur J Clin Pharmacol       Date:  1994       Impact factor: 2.953

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.